Combinations of Lysostaphin with Beta-lactams Are Synergistic Against Oxacillin-resistant Staphylococcus Epidermidis

Overview

Journal Antimicrob Agents Chemother

Publisher American Society for Microbiology

Specialty Pharmacology

Date 2002 May 23

PMID 12019130

Citations 28

Authors

Nandini Kiri

Gordon Archer

Michael W Climo

Affiliations

Soon will be listed here.

Abstract

Oxacillin-resistant Staphylococcus aureus is rapidly killed by the endopeptidase lysostaphin, and the addition of beta-lactam antibiotics provides synergistic killing. We investigated the possibility that beta-lactams given in combination with lysostaphin would improve the activity of lysostaphin against oxacillin-resistant Staphylococcus epidermidis (ORSE), which is normally less susceptible to lysostaphin. Checkerboard synergy testing was performed for lysostaphin given in combination with oxacillin against 10 ORSE isolates for which the lysostaphin MICs were > o r= 8 microg/ml. The fractional inhibitory concentration index ranged from 0.0234 to 0.2656, indicating synergy, which was confirmed in growth curve experiments. In the rabbit model of experimental aortic valve endocarditis using an ORSE strain, the combination of lysostaphin and nafcillin was as effective as vancomycin alone and significantly better than lysostaphin or nafcillin alone. We conclude that beta-lactam antibiotics given in combination with lysostaphin are synergistic against many strains of ORSE.

Citing Articles

Chimeric Peptidoglycan Hydrolases Kill Staphylococcal Mastitis Isolates in Raw Milk and within Bovine Mammary Gland Epithelial Cells.

Keller A, Ly S, Daetwyler S, Eichenseher F, Loessner M, Schmelcher M Viruses. 2022; 14(12).

PMID: 36560804 PMC: 9781970. DOI: 10.3390/v14122801.

Recent Advances in Multifunctional Hydrogels for the Treatment of Osteomyelitis.

Xin W, Gao Y, Yue B Front Bioeng Biotechnol. 2022; 10:865250.

PMID: 35547176 PMC: 9081433. DOI: 10.3389/fbioe.2022.865250.

Targeted Antimicrobial Photodynamic Therapy of Biofilm-Embedded and Intracellular Staphylococci with a Phage Endolysin's Cell Binding Domain.

Bispo M, Santos S, Melo L, Azeredo J, van Dijl J Microbiol Spectr. 2022; 10(1):e0146621.

PMID: 35196798 PMC: 8865409. DOI: 10.1128/spectrum.01466-21.

Design and High Expression of Non-glycosylated Lysostaphins in and Their Pharmacodynamic Study.

Shen W, Yang N, Teng D, Hao Y, Ma X, Mao R Front Microbiol. 2021; 12:637662.

PMID: 33815324 PMC: 8012855. DOI: 10.3389/fmicb.2021.637662.

Deimmunized Lysostaphin Synergizes with Small-Molecule Chemotherapies and Resensitizes Methicillin-Resistant to β-Lactam Antibiotics.

Fang Y, Kirsch J, Li L, Brooks S, Heim S, Tan C Antimicrob Agents Chemother. 2020; 65(3).

PMID: 33318001 PMC: 8092544. DOI: 10.1128/AAC.01707-20.

References

Domaracki B, Evans A, Preston K, Fraimow H, Venezia R . Increased oxacillin activity associated with glycopeptides in coagulase-negative staphylococci. Eur J Clin Microbiol Infect Dis. 1998; 17(3):143-50. DOI: 10.1007/BF01691109. View

Schaberg D, Culver D, Gaynes R . Major trends in the microbial etiology of nosocomial infection. Am J Med. 1991; 91(3B):72S-75S. DOI: 10.1016/0002-9343(91)90346-y. View

Schaffner W, MELLY M, Hash J, KOENIG M . Lysostaphin: an enzymatic approach to staphylococcal disease. I. In vitro studies. Yale J Biol Med. 1967; 39(4):215-29. PMC: 2591270. View

Stranden A, Ehlert K, Labischinski H, Berger-Bachi B . Cell wall monoglycine cross-bridges and methicillin hypersusceptibility in a femAB null mutant of methicillin-resistant Staphylococcus aureus. J Bacteriol. 1997; 179(1):9-16. PMC: 178655. DOI: 10.1128/jb.179.1.9-16.1997. View

Ehlert K, Schroder W, Labischinski H . Specificities of FemA and FemB for different glycine residues: FemB cannot substitute for FemA in staphylococcal peptidoglycan pentaglycine side chain formation. J Bacteriol. 1997; 179(23):7573-6. PMC: 179711. DOI: 10.1128/jb.179.23.7573-7576.1997. View

Oldham E, Daley M . Lysostaphin: use of a recombinant bactericidal enzyme as a mastitis therapeutic. J Dairy Sci. 1991; 74(12):4175-82. DOI: 10.3168/jds.S0022-0302(91)78612-8. View

Tschierske M, Ehlert K, Stranden A, Berger-Bachi B . Lif, the lysostaphin immunity factor, complements FemB in staphylococcal peptidoglycan interpeptide bridge formation. FEMS Microbiol Lett. 1997; 153(2):261-4. DOI: 10.1016/s0378-1097(97)00234-6. View

Sugai M, Fujiwara T, Ohta K, Komatsuzawa H, Ohara M, Suginaka H . epr, which encodes glycylglycine endopeptidase resistance, is homologous to femAB and affects serine content of peptidoglycan cross bridges in Staphylococcus capitis and Staphylococcus aureus. J Bacteriol. 1997; 179(13):4311-8. PMC: 179255. DOI: 10.1128/jb.179.13.4311-4318.1997. View

Stark F, Thornsvard C, Flannery E, Artenstein M . Systemic lysostaphin in man--apparent antimicrobial activity in a neutropenic patient. N Engl J Med. 1974; 291(5):239-40. DOI: 10.1056/NEJM197408012910507. View

10.

Archer G, Climo M . Antimicrobial susceptibility of coagulase-negative staphylococci. Antimicrob Agents Chemother. 1994; 38(10):2231-7. PMC: 284723. DOI: 10.1128/AAC.38.10.2231. View

11.

Kopp U, Roos M, Wecke J, Labischinski H . Staphylococcal peptidoglycan interpeptide bridge biosynthesis: a novel antistaphylococcal target?. Microb Drug Resist. 1996; 2(1):29-41. DOI: 10.1089/mdr.1996.2.29. View

12.

Schaffner W, MELLY M, KOENIG M . Lysostaphin: an enzymatic approach to staphylococcal disease. II. In vivo studies. Yale J Biol Med. 1967; 39(4):230-44. PMC: 2591258. View

13.

PERLMAN B, FREEDMAN L . Experimental endocarditis. II. Staphylococcal infection of the aortic valve following placement of a polyethylene catheter in the left side of the heart. Yale J Biol Med. 1971; 44(2):206-13. PMC: 2591716. View

14.

Climo M, Ehlert K, Archer G . Mechanism and suppression of lysostaphin resistance in oxacillin-resistant Staphylococcus aureus. Antimicrob Agents Chemother. 2001; 45(5):1431-7. PMC: 90484. DOI: 10.1128/AAC.45.5.1431-1437.2001. View

15.

Robinson J, HARDMAN J, Sloan G . Relationship between lysostaphin endopeptidase production and cell wall composition in Staphylococcus staphylolyticus. J Bacteriol. 1979; 137(3):1158-64. PMC: 218296. DOI: 10.1128/jb.137.3.1158-1164.1979. View

16.

Dixon R, Goodman J, KOENIG M . Lysostaphin: an enzymatic approach to staphylococcal disease. 3. Combined lysostaphin-methicillin therapy of established staphylococcal abscesses in mice. Yale J Biol Med. 1968; 41(1):62-8. PMC: 2591441. View

17.

Patron R, Climo M, Goldstein B, Archer G . Lysostaphin treatment of experimental aortic valve endocarditis caused by a Staphylococcus aureus isolate with reduced susceptibility to vancomycin. Antimicrob Agents Chemother. 1999; 43(7):1754-5. PMC: 89356. DOI: 10.1128/AAC.43.7.1754. View

18.

Harrison E, Zygmunt W . Lysostaphin in experimental renal infections. J Bacteriol. 1967; 93(2):520-4. PMC: 276470. DOI: 10.1128/jb.93.2.520-524.1967. View

19.

Climo M, Patron R, Archer G . Combinations of vancomycin and beta-lactams are synergistic against staphylococci with reduced susceptibilities to vancomycin. Antimicrob Agents Chemother. 1999; 43(7):1747-53. PMC: 89355. DOI: 10.1128/AAC.43.7.1747. View

20.

SCHUHARDT V, SCHINDLER C . LYSOSTAPHIN THERAPY IN MICE INFECTED WITH STAPHYLOCOCCUS AUREUS. J Bacteriol. 1964; 88:815-6. PMC: 277390. DOI: 10.1128/jb.88.3.815-816.1964. View